Aetna Cancer Pathways Program Aims For 'Value-Based' Prescribing
This article was originally published in The Pink Sheet Daily
“For many malignancies, there is no ‘best treatment’ but there may be tremendous differences in cost,” Aetna National Medical Director, Oncology Solutions Michael Kolodziej says.
You may also be interested in...
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.